These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17620084)

  • 1. Serotonin and neuroprotection in functional bowel disorders.
    Gershon MD; Liu MT
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2(Suppl 2):19-24. PubMed ID: 17620084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S
    Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
    Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod: a new 5-HT4 agonist.
    Lacy BE; Yu S
    J Clin Gastroenterol; 2002 Jan; 34(1):27-33. PubMed ID: 11743242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G; Snape WJ; Otten MH; Earnest DL; Langaker KE; Pruitt RE; Pecher E; Nault B; Rojavin MA
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1701-8. PubMed ID: 12269961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2002 Aug; 3(8):1211-8. PubMed ID: 12150698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
    Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
    Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C
    Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
    Spiller R
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():25-31. PubMed ID: 17620085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
    Manabe N; Wong BS; Camilleri M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice.
    Liu MT; Kuan YH; Wang J; Hen R; Gershon MD
    J Neurosci; 2009 Aug; 29(31):9683-99. PubMed ID: 19657021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 5-HT(4)-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult.
    Matsuyoshi H; Kuniyasu H; Okumura M; Misawa H; Katsui R; Zhang GX; Obata K; Takaki M
    Neurogastroenterol Motil; 2010 Jul; 22(7):806-13, e226. PubMed ID: 20146727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of serotonin in the pathophysiology of irritable bowel syndrome.
    Crowell MD
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S252-60. PubMed ID: 11474910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome.
    Cole P; Rabasseda X
    Drugs Today (Barc); 2004 Dec; 40(12):1013-30. PubMed ID: 15645012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae.
    Chai W; Chan KY; de Vries R; van den Bogeardt AJ; de Maeyer JH; Schuurkes JA; Villalón CM; Saxena PR; Danser AH; MaassenVanDenBrink A
    Life Sci; 2012 Apr; 90(13-14):538-44. PubMed ID: 22326501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual role of serotonin in the pathogenesis of indomethacin-induced small intestinal ulceration: pro-ulcerogenic action via 5-HT3 receptors and anti-ulcerogenic action via 5-HT4 receptors.
    Kato S; Matsuda N; Matsumoto K; Wada M; Onimaru N; Yasuda M; Amagase K; Horie S; Takeuchi K
    Pharmacol Res; 2012 Sep; 66(3):226-34. PubMed ID: 22699012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and function of 5-HT4 receptors in the mouse enteric nervous system.
    Liu M; Geddis MS; Wen Y; Setlik W; Gershon MD
    Am J Physiol Gastrointest Liver Physiol; 2005 Dec; 289(6):G1148-63. PubMed ID: 16037544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.